Pharming Group to participate in March investor conference
Pharming Group (Nasdaq: PHAR) has announced its participation in the upcoming 37th Annual Roth Conference in Dana Point, California, scheduled for March 16-18, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pharming Group (Nasdaq: PHAR) has announced its participation in the upcoming 37th Annual Roth Conference in Dana Point, California, scheduled for March 16-18, 2025.
The company's Chief Medical Officer Anurag Relan and VP Investor Relations and Corporate Communications Michael Levitan will engage in a fireside chat and Q&A session on March 17, 2025, at 1:30 PM PT/21:30 CET.
Investors interested in one-on-one meetings with Pharming's management team can arrange appointments through the company's Investor Relations team or their Roth representative.
Details
News Market Reaction – PHAR
On Feb 28, the day this news came out, PHAR closed 1.64% above the previous close.
Data tracked by StockTitan Argus for the Feb 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of March:
- 37th Annual Roth Conference, Dana Point, CA, USA, March 16-18, 2025
Anurag Relan, Chief Medical Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Monday, March 17 at 01:30pm PT/21:30 CET.
For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Roth representative.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, United Kingdom
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.